Allied Market Research Publishes Report on Inhaled Nitric Oxide Market
Allied Market Research has published a report on the inhaled nitric oxide market, which provides an in-depth analysis of the market’s current and future prospects.
Market Overview
The inhaled nitric oxide market was valued at $X billion in 2022 and is estimated to reach $X billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032. The growth of the market is attributed to the increasing adoption of inhaled nitric oxide for the treatment of pulmonary disorders in newborns, the rising prevalence of respiratory diseases, and the high research and development activities in this field.
Key Market Segments
By application, the neonatal respiratory treatment segment held the highest market share in 2023, accounting for more than nine-tenths of the inhaled nitric oxide market revenue. This is attributed to the rise in the prevalence of respiratory complications in newborns and the surge in the incidence of preterm births.
By region, North America held the highest market share in 2023, accounting for more than nine-tenths of inhaled nitric oxide market revenue. This is attributed to the surge in research and development activities, well-developed healthcare infrastructure, and rise in the number of preterm births. However, Asia-Pacific is expected to register a noteworthy CAGR during the forecast period, owing to the surge in the prevalence of respiratory diseases, rise in the geriatric population, and increase in disposable income.
Competitive Landscape
The report provides a detailed analysis of the key players in the inhaled nitric oxide market, including their market share, financial performance, product portfolio, and strategic initiatives. The key players profiled in the report include Air Liquide, Linde, Praxair, Messer, and Iwatani.
Future Outlook
The inhaled nitric oxide market is expected to continue growing in the future, driven by the increasing prevalence of respiratory diseases, the rising adoption of inhaled nitric oxide for the treatment of pulmonary disorders, and the high research and development activities in this field.
